Alcuronium chloride

Alcuronium chloride

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	M03AA01 (WHO)
Pharmacokinetic data
Metabolism	not metabolized
Excretion	70-90% unchanged in urine 1.3ml/kg/min t1/2 2- 4 hours
Identifiers
IUPAC name 4,4'-Didemethyl-4,4'-di-propenyltoxiferin-1-dichloride
CAS Number	23214-96-2 N
PubChem CID	5311001
IUPHAR/BPS	341
ChemSpider	20118193 Y
UNII	490DW6501Y
ChEBI	CHEBI:31185 Y
CompTox Dashboard (EPA)	DTXSID0045414
ECHA InfoCard	100.035.648
Chemical and physical data
Formula	C44H50N4O2+2
Molar mass	666.894 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES [Cl-].[Cl-].OC\C=C6\C[N@+]4(CC=C)CC[C@@]58c%11ccccc%11N7\C=C9\[C@H]1C[C@H]2[C@@]%10(CC[N@@+]2(CC=C)C\C1=C\CO)c3ccccc3N(/C=C(/[C@H]6C[C@H]45)[C@H]78)[C@@H]9%10
InChI InChI=1S/C44H50N4O2.2ClH/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49;;/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2;2*1H/q+2;;/p-2/b29-13-,30-14-,33-25-,34-26-;;/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-;;/m0../s1 Y Key:CPYGBGOXCJJJGC-GKLGUMFISA-L Y
NY (what is this?)  (verify)

Alcuronium is a peripherally acting muscle relaxant in the curare alkaloid family. It is a semi-synthetic substance prepared from C-toxiferine I, a bis-quaternary alkaloid obtained from Strychnos toxifera. C-toxiferine I itself was tested for its pharmacological action and noted to be a very long acting neuromuscular blocking agent. Eventually, replacement of both the N-methyl groups with N-allyl moeities yielded N,N-diallyl-bis-nortoxiferine, now recognized as alcuornium and at one time marketed as the proprietary agent called Alloferin.

Inclusion of the allylic functions presented an enhanced potential area of biotransformation, and thus alcuronium is observed to have a much shorter duration of neuromuscular blocking action than its parent C-toxiferine I. It also has a more rapid onset of action, and is ~1.5 times as potent as tubocurarine. The pharmacological action of alcuronium is readily reversed by neostigmine, and it produced little histamine release. The major disadvantage of alcuronium is that it elicits a vagolytic effect produced by a selective atropoine-like blockade of cardiac muscarinic receptors.

Effects

• Cardiovascular system - histamine release and blockage of the sympathetic ganglia including adrenal medulla could cause Hypotension
• Respiratory - apnea due to phrenic blockage but bronchoconstriction can occur from the histamine release
• Central nervous system - no effect on intraoccular pressure
• Autonomic ganglion blockade can cause decrease in gut motility

Special points

• Duration of action prolonger in states of low potassium, calcium and protein, also in states of high magnesium and acidosis.
• Pharmaceutically incompatible with thiopentone
• Infusion can cause fixed dilated pupils

References

• Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K (2002). "Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist". J Pharmacol Exp Ther. 301 (2): 720–8. doi:10.1124/jpet.301.2.720. PMID 11961078.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Maass A, Mohr K (1996). "Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors". Eur J Pharmacol. 305 (1–3): 231–4. doi:10.1016/0014-2999(96)00240-3. PMID 8813558.
• Jakubík J, Tucek S (1994). "Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium". J Neurochem. 63 (5): 1932–40. doi:10.1046/j.1471-4159.1994.63051932.x. PMID 7931349.
• Proska J, Tucek S (1994). "Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors". Mol Pharmacol. 45 (4): 709–17. PMID 8183250.